Refractory Diffuse Large B Cell Lymphoma (DLBCL) research hub
5 indexed studies · 3 currently recruiting
- recruitingPHASE2
DALY II USA/ MB-CART2019.1 for DLBCL
This study is testing a new cell therapy called zamtocabtagene autoleucel for different types of lymphoma, including Diffuse Large B-cell Lymphoma (DLBCL), when other treatments haven't worked. It looks at how well it works and if it's safe.
United States · Canada - recruitingPHASE1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
This study is testing a new medicine called EXS73565 for people with certain types of B-cell cancers that have come back or not responded to usual treatments. We want to find a safe dose and see how it works.
Georgia · Moldova · Spain - active not recruitingPHASE2
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
This study looks at a new combination of three chemotherapy-free drugs for people newly diagnosed with Mantle Cell Lymphoma. It aims to see if this treatment can clear the cancer and if some people can then stop treatment or use just one drug.
United States · Australia · Brazil - recruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
United States · France · Italy - active not recruitingPHASE2
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
This study is testing a new medicine, acalabrutinib (ACP-196), for people with Mantle Cell Lymphoma whose previous treatments haven't worked or stopped working. Researchers want to see how safe and effective this daily tablet is for fighting the cancer.
United States · Australia · Belgium